Cetuximab (Erbitux), a human-murine chimeric monoclonal antibody directed to the EGFR ligand-binding site, has been successfully used to treat some patients with colorectal cancer and HNSCC. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.